Anti-Diabetes Drugs - Ukraine

Ukraine

The Anti-Diabetes Drugs market in Ukraine is projected to witness a significant increase in revenue, reaching US$63.58m by 2024.
This growth is expected to continue at an annual growth rate (CAGR 2024-2029) of 7.49%, leading to a market volume of US$91.23m by 2029.
When compared globally, United States is anticipated to generate the highest revenue in this market, with an estimated US$37,840.00m in 2024.
The demand for anti-diabetes drugs in Ukraine is on the rise due to the increasing prevalence of diabetes in the country.

Key regions: India, Australia, Italy, Europe, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Diabetes Drugs market in Ukraine has been experiencing steady growth in recent years.

Customer preferences: Ukrainian customers tend to prefer affordable and accessible anti-diabetes drugs. The majority of patients suffering from diabetes in Ukraine are either uninsured or have limited access to healthcare services. Therefore, they often opt for generic drugs or those with lower prices.

Trends in the market: The Anti-Diabetes Drugs market in Ukraine has been growing due to the increasing prevalence of diabetes in the country. According to the International Diabetes Federation, Ukraine has one of the highest rates of diabetes in Europe. This has led to an increase in demand for anti-diabetes drugs. Additionally, the Ukrainian government has been implementing healthcare reforms to improve access to healthcare services, which has also contributed to the growth of the market.

Local special circumstances: One of the unique aspects of the Anti-Diabetes Drugs market in Ukraine is the prevalence of counterfeit drugs. Due to the high cost of diabetes treatment, many patients in Ukraine turn to cheaper alternatives, which are often counterfeit. This has led to a significant challenge for legitimate drug manufacturers operating in the country.

Underlying macroeconomic factors: The Ukrainian economy has been experiencing a period of slow growth, which has affected the Anti-Diabetes Drugs market. The high cost of imported drugs has made it difficult for some patients to afford treatment. Additionally, the ongoing conflict in eastern Ukraine has led to a disruption in the supply chain for some drugs, which has further contributed to the challenges faced by the market. However, the Ukrainian government has been implementing reforms to address these issues and improve access to healthcare services, which is expected to have a positive impact on the market in the future.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.